James E. Flynn - 27 Feb 2026 Form 4 Insider Report for Larimar Therapeutics, Inc. (LRMR)

Reporting relationship: Director, * Director by Deputization, 10%+ Owner
Issuer ticker: LRMR
Reported as of: 27 Feb 2026
Net transaction value: +$25,000,000
SEC form: 4
Accepted by SEC: 02 Mar 2026, 19:46:04 UTC
Prior SEC filing: 24 Nov 2025
Next SEC filing: 20 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Isler, Attorney-in-Fact

Key filing fact

James E. Flynn filed Form 4 for Larimar Therapeutics, Inc. (LRMR) on 02 Mar 2026.

Key facts

This page summarizes James E. Flynn's Form 4 filing for Larimar Therapeutics, Inc. (LRMR).
4 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 02 Mar 2026, 19:46.

Change

Previous filing in this sequence was filed on 24 Nov 2025.
Current net transaction value: +$25,000,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (10)

CIK 0001352546 Primary reporting owner

Flynn James E

Relationship: Director, * Director by Deputization, 10%+ Owner
Address: 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK
Signature: /s/ Jonathan Isler, Attorney-in-Fact
Signature date: 02 Mar 2026

CIK 0001009258

DEERFIELD MANAGEMENT COMPANY, L.P.

Relationship: Director, * Director by Deputization, 10%+ Owner
Address: 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK
Signature: /s/ Jonathan Isler, Attorney-in-Fact
Signature date: 02 Mar 2026

CIK 0001610540

Deerfield Mgmt III, L.P.

Relationship: Director, * Director by Deputization, 10%+ Owner
Address: 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK
Signature: /s/ Jonathan Isler, Attorney-in-Fact
Signature date: 02 Mar 2026

CIK 0001665736

Deerfield Mgmt HIF, L.P.

Relationship: Director, * Director by Deputization, 10%+ Owner
Address: 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK
Signature: /s/ Jonathan Isler, Attorney-in-Fact
Signature date: 02 Mar 2026

CIK 0001713467

Deerfield Mgmt IV, L.P.

Relationship: Director, * Director by Deputization, 10%+ Owner
Address: 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK
Signature: /s/ Jonathan Isler, Attorney-in-Fact
Signature date: 02 Mar 2026

CIK 0001010823

Deerfield Mgmt L.P.

Relationship: Director, * Director by Deputization, 10%+ Owner
Address: 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK
Signature: /s/ Jonathan Isler, Attorney-in-Fact
Signature date: 02 Mar 2026

CIK 0001603333

Deerfield Private Design Fund III, L.P.

Relationship: Director, * Director by Deputization, 10%+ Owner
Address: 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK
Signature: /s/ Jonathan Isler, Attorney-in-Fact
Signature date: 02 Mar 2026

CIK 0001646981

Deerfield Healthcare Innovations Fund, L.P.

Relationship: Director, * Director by Deputization, 10%+ Owner
Address: 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK
Signature: /s/ Jonathan Isler, Attorney-in-Fact
Signature date: 02 Mar 2026

CIK 0001680307

Deerfield Private Design Fund IV, L.P.

Relationship: Director, * Director by Deputization, 10%+ Owner
Address: 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK
Signature: /s/ Jonathan Isler, Attorney-in-Fact
Signature date: 02 Mar 2026

CIK 0001301041

DEERFIELD PARTNERS, L.P.

Relationship: Director, * Director by Deputization, 10%+ Owner
Address: 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK
Signature: /s/ Jonathan Isler, Attorney-in-Fact
Signature date: 02 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LRMR transaction

Common Stock

Purchase

Transaction value: $5,420,050
Shares: +1,084,010
Change %: +11%
Price: $5.00
Shares after: 10,622,928
Date: 27 Feb 2026
Ownership: Through Deerfield Private Design Fund III, L.P.
Footnotes: F1, F2

LRMR transaction

Common Stock

Purchase

Transaction value: $5,420,060
Shares: +1,084,012
Change %: +11%
Price: $5.00
Shares after: 10,622,957
Date: 27 Feb 2026
Ownership: Through Deerfield Private Design Fund IV, L.P.
Footnotes: F1, F2

LRMR transaction

Common Stock

Purchase

Transaction value: $4,159,890
Shares: +831,978
Change %: +11%
Price: $5.00
Shares after: 8,153,107
Date: 27 Feb 2026
Ownership: Through Deerfield Healthcare Innovations Fund, L.P.
Footnotes: F1, F2

LRMR transaction

Common Stock

Purchase

Transaction value: $10,000,000
Shares: +2,000,000
Change %: +48%
Price: $5.00
Shares after: 6,207,982
Date: 27 Feb 2026
Ownership: Through Deerfield Partners, L.P.
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. ("Fund III"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. ("Fund IV"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. ("Deerfield HIF"). Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P. ("Deerfield Partners"). Deerfield Management Company, L.P. is the investment manager of Deerfield Partners, L.P., Fund III, Fund IV and Deerfield HIF (collectively, the "Funds"). James E. Flynn is the sole manager of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P., Deerfield Mgmt, L.P. and Deerfield Management Company, L.P.

Footnote F2

In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC remarks

Jonathan S. Leff, a partner in Deerfield Management, serves as a director of the Issuer. Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to BiomX Inc. filed with the Securities and Exchange Commission on March 19, 2024 by Deerfield Private Design Fund V, L.P., Deerfield Healthcare Innovations Fund II, L.P., Deerfield Mgmt V, L.P., Deerfield Mgmt HIF II, L.P., Deerfield Management Company, L.P. and James E. Flynn.